Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ
Closed
Oct 7, 2026
Day's Range
19.5352 wk Range
9.56Overview - AMRX - Amneal Pharmaceuticals, Inc.
Key Statistics
Valuation
Enterprise Value
9.22B
P/E (Trailing)
‪42.29‬
P/E (Forward)
‪17.02‬
PEG Ratio
‪0.26‬
Price / Sales (TTM)
‪2.26‬
Price / Book
‪197.08‬
EV / EBITDA
‪13.38‬
Profitability
Gross Margin
‪42.01%‬
Profit Margin
‪5.04%‬
Operating Margin
‪18.33%‬
Return on Assets
‪8.59%‬
Return on Equity
‪613.01%‬
Ownership
Shares Outstanding
319.33M
Float
197.32M
Short % of Shares Outstanding
‪4.60%‬
Held by Insiders
‪52.09%‬
Held by Institutions
‪48.46%‬
Price stats
Beta
‪1.24‬
50-Day Avg
‪18.27‬
200-Day Avg
‪14.97‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
7 analysts
Average price target
‪$ 20.75‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - AMRX - Amneal Pharmaceuticals, Inc.
Peers - AMRX - Amneal Pharmaceuticals, Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on NASDAQ.
- AMRXNASDAQAmneal Pharmaceuticals, Inc.7.07BMarket Cap+48.03%52-week change42.29P/E (Trailing)‪5.04%‬Profit Margin
- NBIXNASDAQNeurocrine Biosciences, Inc.14.55BMarket Cap+2.62%52-week change20.93P/E (Trailing)‪20.91%‬Profit Margin
- ALKSNASDAQAlkermes plc7.00BMarket Cap+25.77%52-week change109.87P/E (Trailing)‪3.96%‬Profit Margin
- LNTHNASDAQLantheus Holdings Inc.6.52BMarket Cap+47.28%52-week change23.91P/E (Trailing)‪17.69%‬Profit Margin
- KNSANASDAQKiniksa Pharmaceuticals International, plc Class A Ordinary Shares5.83BMarket Cap+49.48%52-week change76.56P/E (Trailing)‪9.59%‬Profit Margin
- DIODNASDAQDiodes Incorporated4.43BMarket Cap+44.79%52-week change51.08P/E (Trailing)‪5.26%‬Profit Margin
- INDVNASDAQIndivior Pharmaceuticals, Inc.4.21BMarket Cap+36.35%52-week change12.68P/E (Trailing)‪26.74%‬Profit Margin
Profile Summary - AMRX - Amneal Pharmaceuticals, Inc.
About
Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes a broad portfolio of essential medicines. Its current business centers on generics, injectables, biosimilars, and specialty branded pharmaceutical products, serving patients and healthcare providers…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
